Specifically, the biomarker profile of epileptic GBM patients compared to non-epileptic cases has been characterized by down-regulation of HIF-1α/hypoxia gene sets and STAT5b target genes, as well as reduced nuclear-phosphorylated STAT5b protein expression [83] (Table 5, Fig. 2). This evidence concerns the gene STAT5B and glioblastoma.